S. Bookbinder

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

Robert Terkeltaub, John S. Sundy, H. Ralph Schumacher et al. · Annals of the Rheumatic Diseases · 2009 · 302 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

Philip J. Mease, Nathan Wei, Edward J. Fudman et al. · The Journal of Rheumatology · 2009 · 112 citations · Full text

Medicine, Clinical Sciences, Immunology +17

The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain

Richard Rauck, S. Bookbinder, T. Bunker et al. · Journal of Opioid Management · 2006 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Methotrexate: its use in the rheumatic diseases.

S. Bookbinder, Luis R. Espinoza, Neil A. Fenske et al. · PubMed · 1985 · 37 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study

Daniel Burge, S. Bookbinder, Alan Kivitz et al. · Clinical Therapeutics · 2008 · 28 citations

Medicine, Pharmacokinetics, Pharmacology +16